The proposed partnership between Charles Drew University (CDU) and UCLA Jonsson Cancer Center seeks to "Eliminate Cancer Health Disparities in iVIinority and Underserved Populations". This objective will continue to strengthen the CDU cancer research and training infrastructure by enhancing the participation of minority students, fellows and faculty engaged in Cancer Research, Training, and Cancer Outreach. The partnership will continue to recruit new faculty with career focus in cancer research, education or outreach. Likewise, UCLA and the investigators in the JCCC will have the important opportunity to address, issues related to the unequal burden of cancer in minority populations. The partnership developed during our U56 funding has made a significant impact on our ability to develop strong pilots and partnership programs. A key new and important addition to our U54 program is the development of strong Cancer Outreach Program and Projects. Thereby, we will train more minority investigators addressing issues in cancer research, education, training and outcome iri our communities. In view of the rapidly changing demographics of Los Angeles and the state of California, the CDU-UCLA Partnership is ideally situated and will have an opportunity to have a positive impact on reducing cancer incidence and improving survival in minority and underserved populations. The overarching goals of the CDU-UCLA Cancer Partnership Program are to significantly increase the number of minority scientists in cancer research and to enhance the cancer outreach programs at CDU to address significant disparities in cancer among minority populations. Supported and implemented by an Administrative Core, Planning and Evaluation Core, and Developmental Core, the basic program components are 1) research projects;2) the mentoring of students and junior investigators;3) the training seminar series;4) enhance CDU's integrated clinical and tissue biorepository data base on minority subjects; 5) enhance community participation;6) improve our clinical trials resource;and 7) increase faculty recruitment. We plan to submit 2 full projects and 2 pilot projects.

Agency
National Institute of Health (NIH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
3U54CA143930-05S1
Application #
8908092
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Moten, Carmen P
Project Start
Project End
Budget Start
Budget End
Support Year
5
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Sarkissyan, Marianna; Wu, Yanyuan; Chen, Zujian et al. (2014) Vitamin D receptor FokI gene polymorphisms may be associated with colorectal cancer among African American and Hispanic participants. Cancer 120:1387-93
Li, Jihong; Vootukuri, Spandana; Shang, Yi et al. (2014) RUC-4: a novel ?IIb?3 antagonist for prehospital therapy of myocardial infarction. Arterioscler Thromb Vasc Biol 34:2321-9
Mathews Griner, Lesley A; Guha, Rajarshi; Shinn, Paul et al. (2014) High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 111:2349-54
Lin, Lehang; Gaut, Daria; Hu, Kaishun et al. (2014) Dual targeting of glioblastoma multiforme with a proteasome inhibitor (Velcade) and a phosphatidylinositol 3-kinase inhibitor (ZSTK474). Int J Oncol 44:557-62
Okamoto, Ryoko; Gery, Sigal; Kuwayama, Yoshio et al. (2014) Novel Gemini vitamin D3 analogs: large structure/function analysis and ability to induce antimicrobial peptide. Int J Cancer 134:207-17
Ceribelli, Michele; Kelly, Priscilla N; Shaffer, Arthur L et al. (2014) Blockade of oncogenic I?B kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 111:11365-70
Maxwell, Annette E; Young, Sandra; Rabelo Vega, Roena et al. (2014) Training Mixtec promotores to assess health concerns in their community: a CBPR pilot study. J Immigr Minor Health 16:310-3
Gery, S; Koeffler, H P (2013) Role of the adaptor protein LNK in normal and malignant hematopoiesis. Oncogene 32:3111-8
Yin, D; Ogawa, S; Kawamata, N et al. (2013) miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32:1155-63
Elshimali, Yahya I; Khaddour, Husseina; Sarkissyan, Marianna et al. (2013) The clinical utilization of circulating cell free DNA (CCFDNA) in blood of cancer patients. Int J Mol Sci 14:18925-58

Showing the most recent 10 out of 16 publications